title: Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.
abstract: Data are limited regarding the use of direct-acting antivirals for treatment of hepatitis C infection post lung transplant, especially in a donor-derived infection. We present a case of a lung transplant recipient with donor-derived hepatitis C that was successfully treated with a 12-week regimen of simeprevir and sofosbuvir. This case reiterates the importance of screening recipients of increased-risk donor organs for disease transmission and the value of early therapy.
authors.affiliation: Division of Infectious Diseases & Immunology, Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Theodoropoulos
authors.affiliation: Division of Cardiac Surgery, Department of Surgery, The Ohio State University (OSU), Columbus, OH, USA.
authors.forename: Bryan A
authors.initials: BA
authors.lastname: Whitson
authors.affiliation: Divsion of Infectious Diseases, Geisinger Health Systems, Danville, PA, USA.
authors.forename: Stanley I
authors.initials: SI
authors.lastname: Martin
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, OSU, Columbus, OH, USA.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Pouch
authors.affiliation: Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Department of Internal Medicine, OSU, Columbus, OH, USA.
authors.forename: Amy
authors.initials: A
authors.lastname: Pope-Harman
mesh_terms: D000328:Adult; D064591:Allografts / Q000382:microbiology / Q000821:virology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077552:Basiliximab; D018562:Disease Transmission, Infectious; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000302:isolation & purification; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006515:Hepatitis B virus / Q000302:isolation & purification; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007165:Immunosuppression Therapy; D007711:Klebsiella pneumoniae / Q000302:isolation & purification; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D016133:Polymerase Chain Reaction; D029424:Pulmonary Disease, Chronic Obstructive / Q000601:surgery; D012367:RNA, Viral / Q000302:isolation & purification; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069616:Simeprevir / Q000008:administration & dosage / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage; D009927:Tissue and Organ Procurement; D066027:Transplant Recipients; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D012367:RNA, Viral; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000069616:Simeprevir; D000069474:Sofosbuvir
keywords: direct-acting antivirals; donor-derived infection; hepatitis C; lung transplant